NCT04104776: A Study of CPI-0209 in Patients With Advanced Solid Tumors

NCT04104776
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known brain metatstases; Patients with prior EZH2 inhibitor therapies
https://ClinicalTrials.gov/show/NCT04104776

Comments are closed.

Up ↑